IBAkteria Sp. z o.o. is the special purpose vehicle of the Institute of Biotechnology and Antibiotics in Warsaw (IBA). The main purpose of the IBAkteria Sp. z o.o. is to commercialize the results obtained in the process of research and development projects.
The Institute has broad experience in cooperating with business entities, which facilitates execution of this objective. IBAkteria Sp. z o.o. and IBA also offer wide range of services.
IBAkteria Sp. z o.o. and the Institute of Biotechnology and Antibiotics provide analytical services for medicinal products, active substances and pharmaceutical ingredients. IBA has integrated quality management system, documented and confirmed by GMP and GLP certificates, which complies with the requirements of Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP) and ISO 9001:2008 standards. IBA also has a GIF-issued manufacturing / import permit for manufacturing, research and quality control of drugs for humans, veterinary products and clinical trial products.
Mission of the Institute
The Institute of Biotechnology and Antibiotics (IBA) is a research institute. The scope of work of the Institute relates to the protection of health and the pharmaceutical industry. IBA employs more than 150 people, including more than 30 research scientists.
Our mission is:
- to conduct scientific research in biotechnology, and the development and implementation of recombinant proteins and other biologically active substances,
- to build up and elevate the reputation and position of the IBA within the scientific communities and in the pharmaceutical sector,
- to disseminate the quality assurance policy for IBA operations.
Realization of Mission
The Institute collaborates with a number of scientific units both in Poland and abroad. The principle of our work in the pharmaceutical and medical domain is to carry out scientific research and to implement the developed technologies into production. We also expand our production based on in-house technology. Our actions are supplemented with a package of services which are contracted by external institutions.
The Institute is the manufacturer of the antineoplastic drug:
Biodribin® (cladribine) – a deoxyadenosine nucleoside derivative used in hairy cell leukaemia, chronic lymphocytic leukaemia and malignant non-Hodgkin’s lymphomas.
We are focused on developing value within areas that are key for us:
Pharmaceutical Biotechnology – genetic engineering of new gene expression systems, genome diagnostics, monoclonal antibodies and the production of highly purified biologically active compounds of a protein structure (e.g. recombined human insulin, growth hormone, interferon).
Chemistry of therapeutic compounds including research and production methods for ß-lactam, aminoglycosides, macrolide and anthracycline antibiotics.